Citi initiated coverage of Scholar Rock (SRRK) with a Buy rating and $55 price target The firm believes concerns over the company’s manufacturing on apitegromab in spinal muscular atrophy are overdone. Citi’s checks indicate a near-term resolution of the manufacturing issues and potential application resubmission approval by Q1 of 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Buy/High Risk: Apitegromab’s Differentiated SMA Profile and Expanding Neuromuscular Upside Support Significant Re-Rating Potential
- Scholar Rock initiated with a Buy at UBS
- Scholar Rock price target raised to $52 from $45 at Barclays
- Scholar Rock Faces FDA Warning, Plans 2026 Launch
- Scholar Rock price target raised to $47 from $46 at JPMorgan